Chronic Fatigue and Dis-Autonomy following COVID-19 Vaccination is Distinguished from Normal Vaccination Response by Altered Blood Markers
,
,
,
,
,
,
,
,
,
,
*
,
A peer-reviewed article of this Preprint also exists.
Semmler, A.; Mundorf, A.K.; Kuechler, A.S.; Schulze-Bosse, K.; Heidecke, H.; Schulze-Forster, K.; Schott, M.; Uhrberg, M.; Weinhold, S.; Lackner, K.J.; Pawlitzki, M.; Meuth, S.G.; Boege, F.; Ruhrländer, J. Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers. Vaccines 2023, 11, 1642. Semmler, A.; Mundorf, A.K.; Kuechler, A.S.; Schulze-Bosse, K.; Heidecke, H.; Schulze-Forster, K.; Schott, M.; Uhrberg, M.; Weinhold, S.; Lackner, K.J.; Pawlitzki, M.; Meuth, S.G.; Boege, F.; Ruhrländer, J. Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers. Vaccines 2023, 11, 1642.
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (2)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
The commenter has declared there is no conflict of interests.
BUT
On the other hand, in my opinion, there is currently to little known about the overall affected diverse deregulated pathways to rule out other parameters that may be affected as well in other subgroups with different symptoms. Therefore, I would remove the sentence "However, the proposed laboratory diagnostic can act as a stringent rule-out criterion allowing future PACVS-studies to focus on the probable cases."
I would not reduce possible parameters at such early a timepoint.
Maybe a more cautious formulation would be better. Something along the line that one can at least already identify a subgroup with these parameters. Restricting laboratory diagnostics too early, when the causes auf the symptomatics are still unclear, can become a disadvantage for diagnostics in the long term.
Especially as long as we don’t know in which cellular RNAs (tRNA, mRNA, rRNA) the N1-Methylpseudouridine of the vaccine might end up, as there is no data on the biodistribution of the nucleotide available at this time point.
“We believe that one objective of future studies should be to draw a clearer and more differentiated clinical picture of PACVS and to use the suggested biomarker signature for patient stratification in a prospective study setting. “
Also here, I would beg to differ, as at the moment I think it would be better to go the opposite way and use a broad omix-like approach, to identify further possible markers and to get a broader overview on future possible makers.
Commenter:
Commenter's Conflict of Interests: I am one of the author